Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.